Cancer Chemotherapy and Pharmacology 1998-01-01

Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial.

D A Garteiz, T Madden, D E Beck, W R Huie, K T McManus, J L Abbruzzese, W Chen, R A Newman

Index: Cancer Chemother. Pharmacol. 41(4) , 299-306, (1998)

Full Text: HTML

Abstract

A highly sensitive and specific assay for the quantitation of the anticancer agent dolastatin-10 (DOL-10) in human plasma is described. The method was based on the use of electrospray ionization-high-performance liquid chromatography/mass spectrometry (ESP-LC/MS). The analytical procedure involved extraction of plasma samples containing DOL-10 and the internal standard (DOL-15) with n-butyl chloride, which was then evaporated under nitrogen. The residue was dissolved in 50 microl mobile phase and 10 microl was subjected to ESP-LC/MS analysis using a C18 microbore column. A linear gradient using water/acetonitrile was used to keep the retention times of the analytes of interest under 5 min. The method exhibited a linear range from 0.005 to 50 ng/ml with a lower limit of quantitation (LLQ) at 0.005 ng/ml. Absolute recoveries of extracted samples in the 85-90% range were obtained. The method's accuracy (< or =5% relative error) and precision (< or =10% CV) were well within industry standards. The analytical procedure was applied to extract DOL-10 metabolites from samples obtained following incubation of the drug with an activated S9 rat liver preparation. Two metabolic products were detected and were tentatively identified as a N-demethyl-DOL-10 and hydroxy-DOL-10. Structural assignments were made based on the fragmentation patterns obtained using the electrospray source to produce collision-induced dissociation (CID). The method was also applied to the measurement of DOL-10 in the plasma of patients treated with this drug. Preliminary investigation of the pharmacokinetics suggested that drug distribution and elimination may be best described by a three-compartment model with t1/2alpha = 0.087 h, t1/2beta = 0.69 h and t1/2gamma = 8.0 h. Plasma clearance was 3.7 l/h per m2.


Related Compounds

Related Articles:

End-binding proteins sensitize microtubules to the action of microtubule-targeting agents.

2013-05-28

[Proc. Natl. Acad. Sci. U. S. A. 110(22) , 8900-5, (2013)]

The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma.

1995-06-01

[Anticancer Drugs 6(3) , 392-7, (1995)]

Effects of dolastatins on human B-lymphocytic leukemia cell lines.

1993-04-01

[Leuk. Res. 17(4) , 333-9, (1993)]

Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.

2012-09-01

[Cancer Chemother. Pharmacol. 70(3) , 439-49, (2012)]

A natural peptide, dolastatin 15, induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells.

2007-06-01

[Int. J. Oncol. 30(6) , 1453-9, (2007)]

More Articles...